An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics and vaccines. This study reports the design and engineering of a recombinant protein designated HR1LS. It contains three lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinling, Sun, Lujia, Liu, Zezhong, Xing, Lixiao, Zhu, Yun, Xu, Wei, Xia, Shuai, Lu, Lu, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424610/
https://www.ncbi.nlm.nih.gov/pubmed/37534910
http://dx.doi.org/10.1080/22221751.2023.2244084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424610/
https://www.ncbi.nlm.nih.gov/pubmed/37534910
http://dx.doi.org/10.1080/22221751.2023.2244084

Ejemplares similares